Health Yuan: Achieve revenue of 15.216 billion yuan by 2025, with more than ten core products already advanced to Phase II clinical trials and subsequent stages.

LightningPacketLoss · 2026-04-03T16:42:07+00:00

Health Yuan Pharmaceutical achieved an operating revenue of 15.216 billion yuan, a net profit of 1.336 billion yuan, and a net cash flow of 3.892 billion yuan in 2025, representing a year-on-year increase of 7.03%. Core products such as Marcipiravir capsules have been approved and advanced to Phase II clinical trials, with a clear strategic layout.

LightningPacketLoss

2026-04-03 16:42:07

Abstract generation in progress

On March 31, 3SBio Group Co., Ltd. disclosed its 2025 annual report. In 2025, the company recorded operating revenue of RMB 15.216 billion. Net profit attributable to shareholders of the listed company was RMB 1.336 billion; net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 1.307 billion, maintaining a steady level. Net cash flow from operating activities reached RMB 3.892 billion, up 7.03% year over year.

The announcement mentioned that in 2025, Marpacyvir Sheawei Capsules (Yili Kang) were approved for listing, and more than ten key product lines have been steadily advanced to Phase II clinical trials and subsequent stages, with the strategic layout in key areas such as respiratory, anti-infection, and analgesia becoming increasingly clear.

(3SBio announcement)

(Edit: Yang Yan, Lin Chen)

Keywords:

                                                            Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.